The Ohio State University Wexner Medical Center
Internal Medicine residency · Columbus, OH · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The Ohio State University Wexner Medical Center's research in internal medicine, which the program shares with other departments and affiliated hospitals.
About The Ohio State University Wexner Medical Centerinstitution-wide internal medicine research
Internal Medicine publications from The Ohio State University Wexner Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
856
works per year
43rd of 129 internal medicine residency programs
+13.3%
2-year growth
42nd of 129 internal medicine residency programs
27.0%
in top 10% of field (works before 2025)
40th of 120 internal medicine residency programs
45.0%
cited above world average
58th of 120 internal medicine residency programs
Works per year · * 2026 so far
Oncology · 1,287Pulmonary and Respiratory Medicine · 926Cardiology and Cardiovascular Medicine · 487Hematology · 398Hepatology · 274
Internal Medicine research topics at The Ohio State University Wexner Medical Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 242
- Hepatocellular Carcinoma Treatment and Prognosis 236
- Pancreatic and Hepatic Oncology Research 190
- Acute Myeloid Leukemia Research 149
- Brain Metastases and Treatment 118
- Cancer survivorship and care 109
- CAR-T cell therapy research 108
- Sarcoma Diagnosis and Treatment 107
Most cited at The Ohio State University Wexner Medical Center since 2024
All internal medicine papers there on OpenAlex
- Non–Small Cell Lung Cancer, Version 4.2024Gregory J. Riely et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 897
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid CancerMatthew David Ringel et al. · Thyroid · 2025 · PubMed · cited 835
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyAl B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 406
- Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trialSandra P. D’Angelo et al. · The Lancet · 2024 · PubMed · cited 319
- NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024Al B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 312
- Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C. Issa et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 262
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 243
- Alternative Complement Pathway Inhibition with Iptacopan in IgA NephropathyVlado Perkovic et al. · New England Journal of Medicine · 2024 · PubMed · cited 229
- CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis et al. · Nature · 2024 · PubMed · cited 201
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaNaresh Bumma et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 201